Literature DB >> 26231832

[Adult onset Still's disease with small vessel vasculitis].

P Hoff1, B F Hoyer, U Schneider, C Kneitz, G-R Burmester, F Buttgereit.   

Abstract

This article presents a particularly severe case of adult onset Still's disease aggravated by small vessel vasculitis. A satisfactory therapy was concluded 1.5 years after onset of the disease. The small vessel vasculitis was difficult to treat: methotrexate (MTX), cyclophosphamide and rituximab were not sufficiently effective. Tocilizumab in combination with intravenous immunoglobulin (IVIG) induced remission and maintenance therapy was carried out with tocilizumab.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26231832     DOI： 10.1007/s00393-015-1623-0

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN： 0340-1855            Impact factor:   1.372


  8 in total

1.  Tocilizumab: a novel therapy for patients with large-vessel vasculitis.

Authors:  Carlo Salvarani; Luca Magnani; Mariagrazia Catanoso; Nicolò Pipitone; Annibale Versari; Lucia Dardani; Lia Pulsatelli; Riccardo Meliconi; Luigi Boiardi
Journal:  Rheumatology (Oxford)       Date:  2011-11-10       Impact factor: 7.580

2.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Authors:  John H Stone; Peter A Merkel; Robert Spiera; Philip Seo; Carol A Langford; Gary S Hoffman; Cees G M Kallenberg; E William St Clair; Anthony Turkiewicz; Nadia K Tchao; Lisa Webber; Linna Ding; Lourdes P Sejismundo; Kathleen Mieras; David Weitzenkamp; David Ikle; Vicki Seyfert-Margolis; Mark Mueller; Paul Brunetta; Nancy B Allen; Fernando C Fervenza; Duvuru Geetha; Karina A Keogh; Eugene Y Kissin; Paul A Monach; Tobias Peikert; Coen Stegeman; Steven R Ytterberg; Ulrich Specks
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

3.  Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

Authors:  Rachel B Jones; Jan Willem Cohen Tervaert; Thomas Hauser; Raashid Luqmani; Matthew D Morgan; Chen Au Peh; Caroline O Savage; Mårten Segelmark; Vladimir Tesar; Pieter van Paassen; Dorothy Walsh; Michael Walsh; Kerstin Westman; David R W Jayne
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

Review 4.  Rheumatoid vasculitis: an update.

Authors:  Ashima Makol; Eric L Matteson; Kenneth J Warrington
Journal:  Curr Opin Rheumatol       Date:  2015-01       Impact factor: 5.006

5.  Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica.

Authors:  S Unizony; L Arias-Urdaneta; E Miloslavsky; S Arvikar; A Khosroshahi; B Keroack; J R Stone; J H Stone
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-11       Impact factor: 4.794

Review 6.  Biological therapy for systemic vasculitis: a systematic review.

Authors:  Lucía Silva-Fernández; Estíbaliz Loza; Víctor M Martínez-Taboada; Ricardo Blanco; Iñigo Rúa-Figueroa; José María Pego-Reigosa; Santiago Muñoz-Fernández
Journal:  Semin Arthritis Rheum       Date:  2013-08-24       Impact factor: 5.532

Review 7.  Treatment of adult-onset Still's disease: a review.

Authors:  Yvan Jamilloux; Mathieu Gerfaud-Valentin; Thomas Henry; Pascal Sève
Journal:  Ther Clin Risk Manag       Date:  2014-12-22       Impact factor: 2.423

Review 8.  State of the art in the treatment of systemic vasculitides.

Authors:  Raashid Ahmed Luqmani
Journal:  Front Immunol       Date:  2014-10-13       Impact factor: 7.561
  8 in total
  1 in total

1.  Unusual manifestations and unusual mimics of adult onset Still's disease.

Authors:  Marwan H Adwan; Faris G Bakri; Ahmad Z Qureshi
Journal:  Saudi Med J       Date:  2017-04       Impact factor: 1.484
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.